Clinical Trial

A Phase 2/3 Interventional Study Of PF-08634404 In Combination With Chemotherapy In Treatment-Naïve Participants With Locally Advanced Or Metastatic Gastric, Gastroesophageal Junction, Or Esophageal Adenocarcinoma

MOA: PF-08634404 is a recombinant anti-PD-1 and anti-VEGF human mAb

Key Eligibility Criteria:

• Histologically or cytologically confirmed gastric, GEJ, or esophageal adenocarcinoma that is locally advanced unresectable or metastatic
• No prior systemic therapy for advanced or metastatic disease
• Subjects should have PD-L1 tumor expression (TAP ≥1% or CPS ≥1) and HER2-negative status based on local testing results
• Subjects with squamous cell or undifferentiated gastroesophageal cancer are excluded
• Subjects with prior exposure to anti-VEGF therapy or cancer immunotherapy, including but not limited to anti-PD-1/PD-L1 therapy are excluded